Gladman DD. Psoriatic arthritis. Dermatol Ther. 2009;22:40–55.

Article  PubMed  Google Scholar 

Scotti L, Franchi M, Marchesoni A, Corrao G. Prevalence and incidence of psoriatic arthritis: a systematic review and meta-analysis. Semin Arthritis Rheum. 2018;48:28–34.

Article  PubMed  Google Scholar 

Van den Bosch F, Coates L. Clinical management of psoriatic arthritis. Lancet. 2018;391:2285–94.

Article  PubMed  Google Scholar 

Ohara Y, Kishimoto M, Takizawa N, Yoshida K, Okada M, Eto H, et al. Prevalence and clinical characteristics of psoriatic arthritis in Japan. J Rheumatol. 2015;42:1439–42.

Article  CAS  PubMed  Google Scholar 

Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376:957–70.

Article  PubMed  Google Scholar 

Kishimoto M, Deshpande GA, Fukuoka K, Kawakami T, Ikegaya N, Kawashima S, et al. Clinical features of psoriatic arthritis. Best Pract Res Clin Rheumatol. 2021;35:101670.

Article  PubMed  Google Scholar 

Gupta S, Syrimi Z, Hughes DM, Zhao SS. Comorbidities in psoriatic arthritis: a systematic review and meta-analysis. Rheumatol Int. 2021;41:275–84.

Article  PubMed  PubMed Central  Google Scholar 

Karmacharya P, Ogdie A, Eder L. Psoriatic arthritis and the association with cardiometabolic disease: a narrative review. Ther Adv Musculoskelet Dis. 2021;13:1759720.

Article  Google Scholar 

FitzGerald O, Ogdie A, Chandran V, Coates LC, Kavanaugh A, Tillett W, et al. Psoriatic arthritis. Nat Rev Dis Primers. 2021;7:59.

Article  PubMed  Google Scholar 

Lo Monaco M, Mallaci Bocchio R, Natoli G, Giardina A, Cangemi I, Scibetta S, et al. Critical importance of patient-reported outcomes for a comprehensive assessment of psoriatic arthritis patients. Front Med. 2024;2024:10. https://doi.org/10.3389/fmed.2023.1332432/full.

Article  Google Scholar 

D’Angiolella LS, Cortesi PA, Lafranconi A, Micale M, Mangano S, Cesana G, et al. Cost and cost effectiveness of treatments for psoriatic arthritis: a systematic literature review. Pharmacoeconomics. 2018;36:567–89.

Article  PubMed  Google Scholar 

Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, et al. Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Rheumatol. 2019;71:5–32.

Article  PubMed  Google Scholar 

Gossec L, Baraliakos X, Kerschbaumer A, de Wit M, McInnes I, Dougados M, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79:700–12.

Article  PubMed  Google Scholar 

Gossec L, Kerschbaumer A, Ferreira RJO, Aletaha D, Baraliakos X, Bertheussen H, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann Rheum Dis. 2024;83:706–19.

Article  CAS  PubMed  Google Scholar 

Coates LC, Kavanaugh A, Mease PJ, Soriano ER, Laura Acosta-Felquer M, Armstrong AW, et al. Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol. 2016;68:1060–71.

Article  PubMed  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.

Article  PubMed  PubMed Central  Google Scholar 

Drummond M. Methods for the economic evaluation of health care programmes. 4th ed. Oxford, New York: Oxford University Press; 2015.

Google Scholar 

Hopson S, Gibbs LR, Syed S, Low R, McClung L, Beaty S. Treatment patterns and healthcare resource utilization among newly diagnosed psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa patients with past diagnosis of an inflammatory condition: a retrospective cohort analysis of claims data in the United States. Adv Ther. 2023;40:4358–76.

Article  PubMed  PubMed Central  Google Scholar 

Bergman MJ, Zueger P, Patel J, Saffore CD, Topuria I, Cavanaugh C, et al. Clinical and economic benefit of achieving disease control in psoriatic arthritis and ankylosing spondylitis: a retrospective analysis from the OM1 registry. Rheumatol Ther. 2023;10:187–99.

PubMed  Google Scholar 

Zagni E, Frassi M, Mariano GP, Fusaro E, Lomater C, Del Medico P, et al. A real-world economic analysis of biologic therapies for psoriatic arthritis in Italy: results of the CHRONOS observational longitudinal study. BMC Health Serv Res. 2022;22:1537.

Article  PubMed  PubMed Central  Google Scholar 

Sewerin P, Borchert K, Meise D, Schneider M, Mahlich J. Health resource utilization and associated health care costs of biologic disease-modifying antirheumatic drugs in german patients with psoriatic arthritis. Arthritis Care Res (Hobok). 2022;74:1435–43.

Article  Google Scholar 

Ogdie A, Hwang M, Veeranki P, Portelli A, Sison S, Shafrin J, et al. Health care utilization and costs associated with functional status in patients with psoriatic arthritis. J Manag Care Spec Pharm. 2022;28:997–1007.

PubMed  Google Scholar 

Merola JF, Dennis N, Chakravarty SD, Villacorta R, Mesana L, Lin I, et al. Healthcare utilization and costs among patients with psoriasis and psoriatic arthritis in the USA-a retrospective study of claims data from 2009 to 2020. Clin Rheumatol. 2021;40:4061–70.

Article  CAS  PubMed  Google Scholar 

Merola JF, Herrera V, Palmer JB. Direct healthcare costs and comorbidity burden among patients with psoriatic arthritis in the USA. Clin Rheumatol. 2018;37:2751–61.

Article  PubMed  Google Scholar 

Orbai AM, Reddy SM, Dennis N, Villacorta R, Peterson S, Mesana L, et al. Work absenteeism and disability associated with psoriasis and psoriatic arthritis in the USA-a retrospective study of claims data from 2009 TO 2020. Clin Rheumatol. 2021;40:4933–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Santos-Moreno P, Gómez-De-la-Rosa F, Parra-Padilla D, Alvis-Zakzuk NJ, Alvis-Zakzuk RN, Carrasquilla-Sotomayor M, et al. Frequency of health care resource utilization and direct medical costs associated with psoriatic arthritis in a rheumatic care center in Colombia. Psoriasis Auckl. 2021;11:31–9.

PubMed  PubMed Central  Google Scholar 

Wu JJ, Pelletier C, Ung B, Tian M, Khilfeh I, Curtis JR. Treatment switch patterns and healthcare costs in biologic-naive patients with psoriatic arthritis. Adv Ther. 2020;37:2098–115.

Article  PubMed  PubMed Central  Google Scholar 

McHugh N, Maguire Á, Handel I, Tillett W, Morris J, Hawkins N, et al. Evaluation of the economic burden of psoriatic arthritis and the relationship between functional status and healthcare costs. J Rheumatol. 2020;47:701–7.

Article  PubMed  Google Scholar 

Thomsen SF, Skov L, Dodge R, Hedegaard MS, Kjellberg J. Socioeconomic costs and health inequalities from psoriasis: a cohort study. Dermatology. 2019;235:372–9.

Article  PubMed  Google Scholar 

Lee S, Xie L, Wang Y, Vaidya N, Baser O. Comorbidity and economic burden among moderate-to-severe psoriasis and/or psoriatic arthritis patients in the US Department of Defense population. J Med Econ. 2018;21:564–70.

Article  PubMed  Google Scholar 

Lee S, Xie L, Wang Y, Vaidya N, Baser O. Evaluating the effect of treatment persistence on the economic burden of moderate to severe psoriasis and/or psoriatic arthritis patients in the U.S. Department of Defense Population. J Manag Care Spec Pharm. 2018;24:654–63.

PubMed  Google Scholar 

Degli Esposti L, Perrone V, Sangiorgi D, Buda S, Andretta M, Rossini M, et al. Analysis of drug utilization and health care resource consumption in patients with psoriasis and psoriatic arthritis before and after treatment with biological therapies. Biologics. 2018;12:151–8.

Google Scholar 

Svedbom A, Dalén J, Black CM, Kachroo S. Persistence and costs with subcutaneous TNF-alpha inhibitors in immune-mediated rheumatic disease stratified by treatment line. Patient Prefer Adherence. 2017;11:95–106.

Article  PubMed  PubMed Central  Google Scholar 

Dilokthornsakul P, Sawangjit R, Osiri M, Chiowchanwisawakit P, Louthrenoo W, Permsuwan U. Cost-utility analysis of biologic disease-modifying antirheumatic drugs for patients with psoriatic arthritis in Thailand. Value Health Reg Issues. 2023;34:40–7.

Article  PubMed  Google Scholar 

Sigurdardottir V, Engstrom A, Berling P, Olofsson T, Oldsberg L, Sadler S, et al. Cost-effectiveness analysis of bimekizumab for the treatment of active psoriatic arthritis in Sweden. J Med Econ. 2023;26:1190–200.

Article  PubMed